Pharma Industry News

Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients

Data also suggested filgotinib 200mg reduced and eliminated corticosteroid use compared to placeboOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]